Cargando…
Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy
BACKGROUND: Information on impact of race and ethnicity on use and early outcomes of septal reduction therapies (SRTs) for obstructive hypertrophic obstructive cardiomyopathy are limited. METHODS AND RESULTS: Using the National Inpatient Sample from January 2012 through December 2019, we identified...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973566/ https://www.ncbi.nlm.nih.gov/pubmed/36565202 http://dx.doi.org/10.1161/JAHA.122.026661 |
_version_ | 1784898552827215872 |
---|---|
author | Patlolla, Sri Harsha Schaff, Hartzell V. Nishimura, Rick A. Eleid, Mackram F. Geske, Jeffrey B. Ommen, Steve R. |
author_facet | Patlolla, Sri Harsha Schaff, Hartzell V. Nishimura, Rick A. Eleid, Mackram F. Geske, Jeffrey B. Ommen, Steve R. |
author_sort | Patlolla, Sri Harsha |
collection | PubMed |
description | BACKGROUND: Information on impact of race and ethnicity on use and early outcomes of septal reduction therapies (SRTs) for obstructive hypertrophic obstructive cardiomyopathy are limited. METHODS AND RESULTS: Using the National Inpatient Sample from January 2012 through December 2019, we identified all adult admissions with a primary diagnosis of obstructive hypertrophic cardiomyopathy and those undergoing SRT. Predictors of receiving SRT and outcomes including in‐hospital mortality, complications, and resource use were evaluated in racial and ethnic groups. Among a total of 18 895 adult admissions with obstructive hypertrophic cardiomyopathy, SRT was performed in 7255 (38.4%) admissions. Septal myectomy was performed in 4930 (26.1%), while alcohol septal ablation was performed in 2325 (12.3%). In adjusted analysis, Black patient (versus White patient adjusted odds ratio, 0.65 [95% CI, 0.57–0.73]; P<0.001) and Hispanic patient admissions (versus White adjusted odds ratio, 0.78 [95% CI, 0.66–0.92]; P=0.003) were less likely to receive SRT. Among admissions undergoing SRT, in‐hospital mortality was significantly higher for Hispanic (adjusted odds ratio, 3.38 [95% CI, 1.81–6.30], P<0.001) and other racial and ethnic groups (adjusted odds ratio 2.02 [95% CI, 1.00–4.11]; P=0.05) compared with White patient admissions, whereas Black patient admissions had comparable mortality. Black, Hispanic, and other ethnic group patients had higher rates of SRT complications and more frequent dismissals to acute care facilities. CONCLUSIONS: Among obstructive hypertrophic cardiomyopathy hospitalizations, minoritized racial groups were less likely to receive SRT. Importantly, hospitalizations of Hispanic and other ethnic patients undergoing SRT had significantly higher in‐hospital mortality and complication rates. Further studies with granular echocardiographic information to assess indications for SRT are needed to better understand these differences. |
format | Online Article Text |
id | pubmed-9973566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99735662023-03-01 Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy Patlolla, Sri Harsha Schaff, Hartzell V. Nishimura, Rick A. Eleid, Mackram F. Geske, Jeffrey B. Ommen, Steve R. J Am Heart Assoc Original Research BACKGROUND: Information on impact of race and ethnicity on use and early outcomes of septal reduction therapies (SRTs) for obstructive hypertrophic obstructive cardiomyopathy are limited. METHODS AND RESULTS: Using the National Inpatient Sample from January 2012 through December 2019, we identified all adult admissions with a primary diagnosis of obstructive hypertrophic cardiomyopathy and those undergoing SRT. Predictors of receiving SRT and outcomes including in‐hospital mortality, complications, and resource use were evaluated in racial and ethnic groups. Among a total of 18 895 adult admissions with obstructive hypertrophic cardiomyopathy, SRT was performed in 7255 (38.4%) admissions. Septal myectomy was performed in 4930 (26.1%), while alcohol septal ablation was performed in 2325 (12.3%). In adjusted analysis, Black patient (versus White patient adjusted odds ratio, 0.65 [95% CI, 0.57–0.73]; P<0.001) and Hispanic patient admissions (versus White adjusted odds ratio, 0.78 [95% CI, 0.66–0.92]; P=0.003) were less likely to receive SRT. Among admissions undergoing SRT, in‐hospital mortality was significantly higher for Hispanic (adjusted odds ratio, 3.38 [95% CI, 1.81–6.30], P<0.001) and other racial and ethnic groups (adjusted odds ratio 2.02 [95% CI, 1.00–4.11]; P=0.05) compared with White patient admissions, whereas Black patient admissions had comparable mortality. Black, Hispanic, and other ethnic group patients had higher rates of SRT complications and more frequent dismissals to acute care facilities. CONCLUSIONS: Among obstructive hypertrophic cardiomyopathy hospitalizations, minoritized racial groups were less likely to receive SRT. Importantly, hospitalizations of Hispanic and other ethnic patients undergoing SRT had significantly higher in‐hospital mortality and complication rates. Further studies with granular echocardiographic information to assess indications for SRT are needed to better understand these differences. John Wiley and Sons Inc. 2022-12-24 /pmc/articles/PMC9973566/ /pubmed/36565202 http://dx.doi.org/10.1161/JAHA.122.026661 Text en © 2022 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Patlolla, Sri Harsha Schaff, Hartzell V. Nishimura, Rick A. Eleid, Mackram F. Geske, Jeffrey B. Ommen, Steve R. Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy |
title | Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy |
title_full | Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy |
title_fullStr | Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy |
title_full_unstemmed | Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy |
title_short | Impact of Race and Ethnicity on Use and Outcomes of Septal Reduction Therapies for Obstructive Hypertrophic Cardiomyopathy |
title_sort | impact of race and ethnicity on use and outcomes of septal reduction therapies for obstructive hypertrophic cardiomyopathy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973566/ https://www.ncbi.nlm.nih.gov/pubmed/36565202 http://dx.doi.org/10.1161/JAHA.122.026661 |
work_keys_str_mv | AT patlollasriharsha impactofraceandethnicityonuseandoutcomesofseptalreductiontherapiesforobstructivehypertrophiccardiomyopathy AT schaffhartzellv impactofraceandethnicityonuseandoutcomesofseptalreductiontherapiesforobstructivehypertrophiccardiomyopathy AT nishimuraricka impactofraceandethnicityonuseandoutcomesofseptalreductiontherapiesforobstructivehypertrophiccardiomyopathy AT eleidmackramf impactofraceandethnicityonuseandoutcomesofseptalreductiontherapiesforobstructivehypertrophiccardiomyopathy AT geskejeffreyb impactofraceandethnicityonuseandoutcomesofseptalreductiontherapiesforobstructivehypertrophiccardiomyopathy AT ommenstever impactofraceandethnicityonuseandoutcomesofseptalreductiontherapiesforobstructivehypertrophiccardiomyopathy |